[HTML][HTML] Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

K Jamerson, MA Weber, GL Bakris… - … England Journal of …, 2008 - Mass Medical Soc
Background The optimal combination drug therapy for hypertension is not established,
although current US guidelines recommend inclusion of a diuretic. We hypothesized that …

C-reactive protein in heart failure: prognostic value and the effect of valsartan

IS Anand, R Latini, VG Florea, MA Kuskowski… - Circulation, 2005 - Am Heart Assoc
Background—The role of C-reactive protein (CRP) in heart failure is not well studied. We
assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart …

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT

R Latini, S Masson, I Anand, M Salio… - European heart …, 2004 - academic.oup.com
Aims Plasma levels of individual neurohormones (NH) have been proposed as reliable
indicators for risk stratification of patients with heart failure (HF). Mainly because of small …

Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT

IS Anand, MA Kuskowski, TS Rector, VG Florea… - Circulation, 2005 - Am Heart Assoc
Background—Anemia is known to be a prognostic marker for patients with heart failure.
However, little is known about the prognostic value of changes in hemoglobin (Hgb) over …

[HTML][HTML] Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B. 1.617. 2): national case-control study

H Allen, A Vusirikala, J Flannagan… - The Lancet Regional …, 2022 - thelancet.com
Summary Background The SARS-CoV-2 Delta variant (B. 1.617. 2), first detected in India,
has rapidly become the dominant variant in England. Early reports suggest this variant has …

Risk of hospital admission for patients with SARS-CoV-2 variant B. 1.1. 7: cohort analysis

T Nyberg, KA Twohig, RJ Harris, SR Seaman… - bmj, 2021 - bmj.com
Objective To evaluate the relation between diagnosis of covid-19 with SARS-CoV-2 variant
B. 1.1. 7 (also known as variant of concern 202012/01) and the risk of hospital admission …

Cardiovascular events during differing hypertension therapies in patients with diabetes

MA Weber, GL Bakris, K Jamerson, M Weir… - Journal of the American …, 2010 - jacc.org
Objectives: The aim of this study was to determine which combination therapy in patients
with hypertension and diabetes most effectively decreases cardiovascular events …

Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data

M Wong, L Staszewsky, R Latini, S Barlera… - Journal of the American …, 2004 - jacc.org
Objectives: The objective of this study was to test the hypothesis that the severity of left
ventricular remodeling predicts the response to treatment and outcomes in chronic heart …

Comparative transmission of SARS-CoV-2 Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) variants and the impact of vaccination: national cohort study, England

H Allen, E Tessier, C Turner, C Anderson… - Epidemiology & …, 2023 - cambridge.org
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.
1.1. 529) rapidly replaced Delta (B. 1.617. 2) to become dominant in England. Our study …

Exceptional early blood pressure control rates: the ACCOMPLISH trial

K Jamerson, GL Bakris, B Dahlöf, B Pitt… - Blood …, 2007 - Taylor & Francis
Background. ACCOMPLISH is a “new‐generation” hypertension trial assessing single‐tablet
combination therapy for initial treatment of high‐risk hypertension. At baseline, 97% of …